Oral SERDs alone or in combination with CDK 4/6 inhibitors in breast cancer: Current perspectives and clinical trials.

Despite the fact that AMEERA-3 and acelERA BC studies did not reach statistical significance for their primary endpoints, amcenestrant and giredestrant respectively demonstrated numerically longer PFS in a subset of patients with baseline ESR1 mutated tumors [ 84 , 86 ]. 4.

also in 111,027 other papers